Why Vaccinex's Stock Is Trading Lower Today

Vaccinex VCNX shares are trading lower on Wednesday after BTIG downgraded the stock from Buy to Neutral.

Vaccinex is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's product pipeline includes pepinemab (VX15) Neurology, VX5 Autoimmune, and others.

Vaccinex shares were trading down 15.09% at $1.97 at the time of publication. The stock has a 52-week high of $12.23 and a 52-week low of $1.95.